Cullen Frost Bankers Inc. Purchases Shares of 1,248 Ionis Pharmaceuticals Inc (IONS)

Cullen Frost Bankers Inc. bought a new position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,248 shares of the company’s stock, valued at approximately $101,000.

Several other institutional investors have also recently modified their holdings of IONS. Mackay Shields LLC bought a new stake in Ionis Pharmaceuticals in the fourth quarter valued at $1,818,000. Capital Investment Advisory Services LLC bought a new stake in Ionis Pharmaceuticals in the fourth quarter valued at $91,000. BB Biotech AG boosted its holdings in Ionis Pharmaceuticals by 0.9% in the fourth quarter. BB Biotech AG now owns 8,741,334 shares of the company’s stock valued at $472,557,000 after acquiring an additional 75,000 shares in the last quarter. Hanseatic Management Services Inc. bought a new stake in Ionis Pharmaceuticals in the fourth quarter valued at $440,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Ionis Pharmaceuticals by 82.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,709 shares of the company’s stock valued at $957,000 after acquiring an additional 8,014 shares in the last quarter. Hedge funds and other institutional investors own 82.72% of the company’s stock.

Shares of IONS stock traded down $0.62 during mid-day trading on Wednesday, reaching $64.42. 1,390,500 shares of the company’s stock traded hands, compared to its average volume of 1,251,282. Ionis Pharmaceuticals Inc has a 12 month low of $40.91 and a 12 month high of $86.58. The stock has a market cap of $9.03 billion, a PE ratio of 21.76 and a beta of 2.31. The company has a current ratio of 9.40, a quick ratio of 9.36 and a debt-to-equity ratio of 0.47.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Thursday, May 9th. The company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.19. Ionis Pharmaceuticals had a net margin of 47.74% and a return on equity of 44.03%. The firm had revenue of $297.00 million for the quarter, compared to analysts’ expectations of $285.43 million. During the same quarter in the previous year, the business posted ($0.01) EPS. The company’s quarterly revenue was up 106.3% on a year-over-year basis. On average, sell-side analysts forecast that Ionis Pharmaceuticals Inc will post -0.21 earnings per share for the current fiscal year.

Several analysts recently weighed in on the stock. Piper Jaffray Companies set a $75.00 price target on shares of Ionis Pharmaceuticals and gave the company a “neutral” rating in a report on Friday, March 22nd. Cantor Fitzgerald assumed coverage on shares of Ionis Pharmaceuticals in a report on Tuesday, April 9th. They issued a “neutral” rating and a $68.00 price target on the stock. BMO Capital Markets lifted their price target on shares of Ionis Pharmaceuticals to $96.00 and gave the company an “outperform” rating in a report on Monday, April 22nd. Finally, Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a report on Thursday, April 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $66.44.

In other news, Director B Lynne Parshall sold 8,334 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $75.00, for a total transaction of $625,050.00. Following the sale, the director now owns 61,011 shares in the company, valued at approximately $4,575,825. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Frederick T. Muto sold 8,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $72.75, for a total value of $582,000.00. Following the completion of the transaction, the director now directly owns 17,794 shares of the company’s stock, valued at approximately $1,294,513.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 240,556 shares of company stock worth $19,431,650. Company insiders own 2.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://sundanceherald.com/2019/05/29/cullen-frost-bankers-inc-buys-shares-of-1248-ionis-pharmaceuticals-inc-ions.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Further Reading: Liquidity

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply